Dazucorilant

What is the drug thought to do in the body?

Increased levels of cortisol have been seen in people living with MND. High levels of cortisol can increase inflammation and be toxic to nerve cells, which are associated with MND. Dazucorilant blocks the glucocorticoid receptor, which normally binds to cortisol. Blocking cortisol from binding is thought to limit the consequences of increased cortisol exposure and potentially help slow disease progression. In early laboratory testing, Dazucorilant was found to improve motor performance, reduce neuroinflammation and muscular atrophy. 

Phase 2 - DAZALS

Current status: Collecting data

Primary objective: To investigate if Dazucorilant change the rate of disease progression, from baseline to week 24, measured by the ALS functional rating scale (ALSFRS-R).

The phase 2 trial is investigating the safety and efficacy of Dazucorilant by comparing the treatment to a placebo over 24-weeks. The trial is also testing different dosages (150 mg and 300mg), to find the best dose to take forward to further trials. 249 participants were recruited into the trial. Participants who complete the trial will be able to continue into the open-label part of the trial, where all participants have the option to receive the treatment for a further 24-weeks.  Find out more on clinicaltrials.gov.

Last updated: 16/08/2024